---
class: Glycoprotein IIb/IIIa inhibitor
chemistry:
dose:
    antiplatelet:
        - "Load: 180 Âµg/kg"
        - "Maintenance: Weight based. Indications include: high thrombus burden, failed PCI, or prior to surgical revascularisation."
pharmaceutics:
    presentation:
        - 2mg/mL
    stability:
        - Light sensitive in ampoule
        - Incompatible with furosemide
pharmacokinetics:
    absorption:
    distribution:
        pKa:
        vd:
        protein binding:
    metabolism:
        half-life:
        pathway:
        metabolites:
    elimination:
        renal:
mechanism: Inhibits formation of arterial thrombus by preventing fibrinogen, von Willebrand factor and other adhesive
ligands binding to platelets
contraindications:
    - Severe bleeding
    - Risk of intracranial bleeding
    - Ischaemic stroke within 30 days
    - Severe hypertension
pharmacodynamics:
    resp:
    cvs:
    cns:
    endo:
    msk:
    met:
    ren:
    gu:
    git:
    haeme:
        - Thrombocytopenia
        - Full reversal of platelet inhibition after 6 hours
        - Should be ceased 4 hours prior to CABG
        - No effect on PT/APTT